GeneMedi Efficacy Assay/Evaluation Solutions for COVID-19 Vaccines and Therapeutic antibodies against SARS-CoV2(2019nCoV)
To meet accumulated mutating of SARS-CoV-2, GeneMedi keeps continually developing novel solutions and tools for efficacy evaluation of COVID-19 vaccines (and neutralized antibodies) against novel mutant SARS-CoV-2 (2019nCoV) lineages. Our scientist's team takes duty in fighting against the COVID-19 pandemic with our global industrial and academic partners.
1. GeneMedi information and products collection of SARS-COV-2 (2019nCOV) UK B.1.1.7 lineage and South Africa 501Y.V2 lineage and Brazilian P.1 lineage(B.1.1.28.1)
GeneMedi pseudotyped virus (pseudovirus) of SARS-COV-2 (2019nCOV) B.1.1.7 lineage
GeneMedi pseudotyped virus (pseudovirus) of SARS-COV-2 (2019nCOV) 501Y.V2 lineage
GeneMedi pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) P.1 lineage(B.1.1.28.1, Brazilian variant)
SARS-COV-2 (2019nCOV) B.1.1.7 lineage & 501Y.V2 lineage(B.1.351) & P.1 lineage (B.1.1.28.1, Brazilian variant) of Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies
GeneMedi codon-optimized spike mammalian expression vector for SARS-COV-2 (2019nCOV) B.1.1.7 lineage
GeneMedi codon-optimized spike mammalian expression vector for SARS-COV-2 (2019nCOV) South Africa 501Y.V2 lineage(B.1.351).
GeneMedi codon-optimized spike mammalian expression vector for SARS-COV-2 (2019nCOV) - P.1 lineage(B.1.1.28.1, Brazilian variant)
2. Multiple variants of Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies
The Spike proteins variants that GeneMedi offer is including:
1) Multiple variants of recombinant Spike protein for Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies
2) Recombinant human ACE2 protein products
| Cat No. | Antigen Name of 2019-nCoV(SARS-CoV-2) | Isotypes | Order |
| GMP-H-ACE2001 | Recombinant human solubale ACE2 protein (soluble hACE2, extracellular hACE2, C-His) | Mammalian (human cell) |  |
| GMP-H-ACE2002 | Recombinant human solubale ACE2 protein (soluble hACE2, extracellular hACE2, C-His) | Mammalian (human cell) | |
Figure. Immobilized 2019-nCoV S Protein RBD-C-His (GMP-V-2019nCoV-SRBD001) can bind 10μg/ml of Human ACE-2-Fc (GMP-H-ACE2002)
3. Multi-Variants™ SARS-CoV2 (wildtype, D614G, N501Y, E484K, B.1.1.7 lineage, 501Y.V2 lineage, and so on) Pseudotype virus-Based Neutralization Assay System for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies (Lentiviral pseudovirus)
Protocol: GeneMedi SARS-CoV2 pseudovirus-based neutralization assay-protocol  Protocol Download
|
4. Codon-optimized mammalian expression vector for SARS-COV-2 (2019nCOV) spike wide type & mutant variants (D614G, N501Y, E484K, B.1.1.7 lineage, 501Y.V2 lineage, and so on)
Codon-optimized viral particle (Adenovirus, Lentivirus, AAV) for SARS-COV-2 (2019nCOV) spike wide type & mutant variants (D614G, N501Y, E484K, B.1.1.7 lineage, 501Y.V2 lineage, and so on)
5. 293T-ACE2 stable cell line & human ACE2 expression vectors: Effector cell of pseudotype virus-Based Neutralization Assay System for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies (Lentiviral pseudovirus)
Human ACE2 overexpression stable HEK293T cell lines. Catalot Number: GM-SC-293T-hACE2-01 Click here for details| Cat No. | 2019 nCoV related Gene |
Gene &Vector description of 2019 nCoV | Vector | Reporter | Tag | codon Optimized |
Order |
| GMV-V-2019nCoV-045 | TMPRSS2 | pGMLv-hTMPRSS2(C-3FLAG) | Lentiviral vector | Zsgreen | C-3FLAG | No | |
| GMV-V-2019nCoV-041 | ACE2 | pGMLV-hACE2(C-3FLAG) | Lentiviral vector | Zsgreen | C-3FLAG | No | |
| GMV-V-2019nCoV-042 | ACE2 | pAD-hACE2(C-3FLAG) | Pre-made Adenovirus | EGFP | C-3FLAG | No | |
| GMV-V-2019nCoV-046 | TMPRSS2 | pGMLv-mtmprss2(C-3FLAG) | Lentiviral vector | Zsgreen | C-3FLAG | No | |
| GMV-V-2019nCoV-043 | ACE2 | pAD-mACE2(C-3FLAG) | Pre-made Adenovirus | EGFP | C-3FLAG | No | |
| GMV-V-2019nCoV-044 | ACE2 | pGMLV-mACE2(C-3FLAG) | Lentiviral vector | Zsgreen | C-3FLAG | No | |
 |
|
| Figure. ACE2 mRNA level Validation in hACE2 overexpression stable HEK293T cell lines: Cat. GM‐SC‐293T‐hACE2‐01 (A) and the cell lines were tested as Mycoplasma free (B). | |
| Cat No. | 2019 nCoV related Gene |
Gene &Vector description of 2019 nCoV | Vector | Reporter | Tag | codon Optimized |
Order |
| GMV-V-2019nCoV-041 | ACE2 | pGMLV-hACE2(C-3FLAG) | Lentiviral vector | Zsgreen | C-3FLAG | No | |
| GMV-V-2019nCoV-042 | ACE2 | pAD-hACE2(C-3FLAG) | Pre-made Adenovirus | EGFP | C-3FLAG | No | |
| GMV-V-2019nCoV-043 | ACE2 | pAD-mACE2(C-3FLAG) | Pre-made Adenovirus | EGFP | C-3FLAG | No | |
| GMV-V-2019nCoV-044 | ACE2 | pGMLV-mACE2(C-3FLAG) | Lentiviral vector | Zsgreen | C-3FLAG | No | |
6. Validated SARS-CoV-2 neutralizing antibodies-benchmark COVID-19 neutralizing antibodies.
| Cat No. | Antigen Name of 2019-nCoV(SARS-CoV-2) | Source (Expression Host) |
Isotypes | Bioactivity validation | Order |
| GMP-V-2019nCoV-SnAb001 | Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgG1) | Mammalian (human cell) | human IgG1 | Validated in COVID-19 Spike protein and Spike-RBD protein binding affnity. COVID-19 related neutralizing potency is validated by 1.2019nCoV pseudotyped virus based neutralization assay in 293T-ACE2 effector cell. 2. competitively blocking the binding of ACE-2 receptor with SARS-CoV-2 Spike protein. |
|
| GMP-V-2019nCoV-SnAb002 | Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgM) | Mammalian (human cell) | human IgM | Validated in COVID-19 Spike protein and Spike-RBD protein binding affnity. COVID-19 related neutralizing potency is validated by 1.2019nCoV pseudotyped virus based neutralization assay in 293T-ACE2 effector cell. 2. competitively blocking the binding of ACE-2 receptor with SARS-CoV-2 Spike protein. |
|
| GMP-V-2019nCoV-SnAb003 | Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgA) | Mammalian (human cell) | human IgA | Validated in COVID-19 Spike protein and Spike-RBD protein binding affnity. COVID-19 related neutralizing potency is validated by 1.2019nCoV pseudotyped virus based neutralization assay in 293T-ACE2 effector cell. 2. competitively blocking the binding of ACE-2 receptor with SARS-CoV-2 Spike protein. |
|
| GMP-V-2019nCoV-SnAb004 | Anti-2019-nCoV Spike (Spike RBD domain) mouse monoclonal neutralizing antibody (IgG1) | Mammalian (human cell) | mouse IgG1 | Validated in COVID-19 Spike protein and Spike-RBD protein binding affnity. COVID-19 related neutralizing potency is validated by 1.2019nCoV pseudotyped virus based neutralization assay in 293T-ACE2 effector cell. 2. competitively blocking the binding of ACE-2 receptor with SARS-CoV-2 Spike protein. |
|
| GMP-V-2019nCoV-SnAb005 | Anti-2019-nCoV Spike (Spike RBD domain) Cynomolgus monoclonal neutralizing antibody (IgG1) | Mammalian (human cell) | Cynomolgus (Non human primate, NHP) IgG1 | Validated in COVID-19 Spike protein and Spike-RBD protein binding affnity. COVID-19 related neutralizing potency is validated by 1.2019nCoV pseudotyped virus based neutralization assay in 293T-ACE2 effector cell. 2. competitively blocking the binding of ACE-2 receptor with SARS-CoV-2 Spike protein. |
|
 
|
| Figure. The Pseudovirus (PSV) Based Neutralizing Assay was performed on 293T-hACE2 cells infected with GeneMedi-SARS-CoV-2 WT and Spike Mutation Variants (D614G, S943P, V367F, G476S, V483A, H49Y, Q239K, A831V, P1263L, D839Y/N/E:D839Y, D839N, D839E) Pseudovirus (PSV) under treatment of GeneMedi's anti-2019-nCoV Spike Neutralizing antibodies (Nabs) . Inhibition rate was determined by comparing the relative RFP+GFP+/GFP+ rate. |
|
||||||||||||||||||
|
Figure. The binding of GeneMedi's anti-2019-nCoV Spike Neutralizing antibodies (Nabs) to Recombinant 2019-nCoV(SARS-CoV-2) Spike RBD protein (GMP-V-2019nCoV-SRBD001) at 5.0ug/ml (100uL/well) was measured by ELISA. A.GMP-V-2019nCoV-SnAb001:Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgG1) B.GMP-V-2019nCoV-SnAb002:Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgM) C.GMP-V-2019nCoV-SnAb003:Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgA) D.GMP-V-2019nCoV-SnAb004:Anti-2019-nCoV Spike (Spike RBD domain) mouse monoclonal neutralizing antibody (IgG1) E.GMP-V-2019nCoV-SnAb005:Anti-2019-nCoV Spike (Spike RBD domain) Cynomolgus monoclonal neutralizing antibody (IgG1) |
|
||||||||||||||||||
|
Figure. GeneMedi's anti-2019-nCoV Spike Neutralizing antibodies (Nabs) block Recombinant 2019-nCoV(SARS-CoV-2) Spike RBD protein (GMP-V-2019nCoV-SRBD001) and hACE2 (GMP-H-ACE2002) binding. A.GMP-V-2019nCoV-SnAb001:Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgG1) B.GMP-V-2019nCoV-SnAb002:Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgM) C.GMP-V-2019nCoV-SnAb003:Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgA) D.GMP-V-2019nCoV-SnAb004:Anti-2019-nCoV Spike (Spike RBD domain) mouse monoclonal neutralizing antibody (IgG1) E.GMP-V-2019nCoV-SnAb005:Anti-2019-nCoV Spike (Spike RBD domain) Cynomolgus monoclonal neutralizing antibody (IgG1) |
2) Neutralizing antibodies
3) Peptides blockers (peptide inhibitors)
4) Compounds targeting Spike induced cell-fusion.
1. 2 Korber, B. et al. Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2. bioRxiv Preprint., doi:10.1101/2020.04.29.069054 (2020). 2. Investigation of novel SARS-COV-2 variant. Public health England. 3. European Centre for Disease Prevention and Control. Rapid increase of a SARS-CoV-2 variant with multiple spike protein mutations observed in the United Kingdom – 20 December 2020.ECDC: Stockholm; 2020. 4. Li, G. & De Clercq, E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Reviews Drug Discovery, doi:10.1038/d41573-020-00016-0 (2020). 5. Haque, A. & Pant, A. B. Efforts at COVID-19 Vaccine Development: Challenges and Successes. Vaccines 8, doi:10.3390/vaccines8040739 (2020). 6. Dong, Y. et al. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduction and Targeted Therapy 5, doi:10.1038/s41392-020-00352-y (2020). 7. Andrew Rambaut1, N. L., Oliver Pybus, Wendy Barclay, Jeff Barrett5, Alesandro Carabelli6, Tom Connor, Tom Peacock, David L Robertson8, Erik Volz, . Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. https://virological.org/ (2020). 8. Rapid increase of a SARS-CoV-2 variant with multiple spike protein mutations observed in the United Kingdom. European Centre for Disease Prevention and Control: Publications & data. 9. Zhang, L. et al. SARS-CoV-2 RNA reverse-transcribed and integrated into the human genome. bioRxiv Preprint. , doi:10.1101/2020.12.12.422516 (2020).
Facebook
LinkedIn
Twitter
